Edition:
India

3SBio Inc (1530.HK)

1530.HK on Hong Kong Stock

18.96HKD
19 Apr 2018
Change (% chg)

HK$1.26 (+7.12%)
Prev Close
HK$17.70
Open
HK$17.98
Day's High
HK$19.18
Day's Low
HK$17.98
Volume
13,259,079
Avg. Vol
8,046,853
52-wk High
HK$19.64
52-wk Low
HK$9.35

Latest Key Developments (Source: Significant Developments)

3SBio Inc Posts FY Net Profit Attributable RMB935.4 Mln
Monday, 26 Mar 2018 

March 26 (Reuters) - 3Sbio Inc <1530.HK>::FY NET PROFIT ATTRIBUTABLE RMB935.4 MILLION VERSUS RMB712.6 MILLION.RECOMMENDED PAYMENT OF FINAL DIVIDEND OF HKD6.85 CENTS PER ORDINARY SHARE.FY REVENUE UP 33.5% TO RMB3,734.3 MILLION.  Full Article

3Sbio Says Unit And Toray Sign Exclusive Licensing Agreement On Antipuritic Agent, TRK-820​
Monday, 15 Jan 2018 

Jan 15 (Reuters) - 3Sbio Inc <1530.HK>::UNIT AND TORAY ENTER EXCLUSIVE LICENSING AGREEMENT ON CERTAIN ORAL DISINTEGRATION TABLET FORMULATION OF ANTIPRURITIC DRUG TRK-820​.  Full Article

3SBio Says ‍China FDA Approves New Once-Weekly Bydureon To Improve Glycemic Control​
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - 3Sbio Inc <1530.HK>::‍CHINA FDA APPROVES NEW ONCE-WEEKLY BYDUREON TO IMPROVE GLYCEMIC CONTROL​.  Full Article

3SBio Inc says 601a approved by China FDA for clinical trials ​
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - 3SBio Inc <1530.HK>:Recombinant humanized anti-VEGF monoclonal antibody for injection (601a) approved by China FDA for clinical trials ​.  Full Article

3SBio Inc says HY net profit RMB286.9 million<1530.HK>
Monday, 22 Aug 2016 

3SBio Inc <1530.HK>: HY gross profit increased by RMB442.9 million, or 64.2% to RMB1.13 billion . Says HY revenue increased by 65.1% to RMB1.3 billion . Says board does not recommend any interim dividend for the six months ended 30 June 2016 . HY net profit RMB286.9 million versus RMB242.5 million .  Full Article

3SBio Inc gets Investigational New Drug application for its drug from China Food and Drug Administration<1530.HK>
Friday, 12 Aug 2016 

3SBio Inc <1530.HK>: Voluntary announcement <1530.HK> . Announced that its anti-epidermal growth factor receptor monoclonal antibody has received an approval of investigational new drug application for clinical trial .  Full Article

3SBio says trifluridine and tipiracil hydrochloride tablet has received clinical trial approval<1530.HK>
Thursday, 7 Jul 2016 

3SBio Inc <1530.HK>: Trifluridine and tipiracil hydrochloride tablet has received clinical trial approval from the China food and drug administration .  Full Article

Sorrento, 3Sbio announce CAR-T joint venture in China
Tuesday, 7 Jun 2016 

Sorrento Therapeutics Inc : 3Sbio will make total contributions of $10 million to joint venture . 3Sbio will initially own 51% of joint venture while TNK will initially hold remaining 49%. . tnk will grant JV exclusive license to CEA CAR-T technology and two additional CARS for cellular therapy for greater china market .Sorrento And 3Sbio Announce CAR-T joint venture in China.  Full Article

3SBio updates on establishment of joint venture and purchase of securities<1530.HK>
Tuesday, 7 Jun 2016 

3SBio Inc <1530.HK>: Voluntary announcement - establishment of a joint venture and purchase of securities <1530.HK> . Unit entered into a legally binding term sheet with TNK Therapeutics . Says Shenyang sunshine is expected to make an initial contribution of US$10 million to the joint venture .  Full Article

3SBio says unit intends to withdraw drug application for 'Ipterbin'<1530.HK>
Thursday, 19 May 2016 

3SBio Inc <1530.HK>: Unit intends to withdraw drug application for ipterbin developed for treatment of her2 over-expressing metastatic breast cancer .Does not expect intended application withdrawal to have significant impact on group's current and future operating and financial performance.  Full Article

BRIEF-3SBio Announces Tpiao Injection gets Approval For Clinical Trials For Additional Indication By CFDA

* TPIAO INJECTION GRANTED APPROVAL FOR CLINICAL TRIALS FOR ADDITIONAL INDICATION BY CHINA FOOD AND DRUG ADMINISTRATION​ Source text for Eikon: Further company coverage: